Search results for " IMMUNOTHERAPY"

showing 10 items of 272 documents

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

2021

Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Amo…

Malelcsh:Immunologic diseases. AllergyCD3Immunologychemical and pharmacologic phenomenaBacillus Calmette–GuerinLymphocyte ActivationCancer VaccinesImmunotherapy AdoptiveCohort StudiesBasal (phylogenetics)Tumor Necrosis Factor Receptor Superfamily Member 9Lymphocytes Tumor-InfiltratingmedicineImmunology and AllergyHumansadoptive cellular immunotherapyLymph nodeCells CulturedAgedCell ProliferationOriginal Researchmolecular subtypesBladder cancerbiologyTumor-infiltrating lymphocytesbusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseMycobacterium bovismedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic Metastasistumor-infiltrating lymphocytesCancer researchbiology.proteinInterleukin-2bladder cancerFemaleLymphAntibodyUrotheliumbusinesslcsh:RC581-607CD8Frontiers in Immunology
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis.

2005

Contains fulltext : 48023.pdf (Publisher’s version ) (Closed access) OBJECTIVE: Heme oxygenase 1 (HO-1) can be induced by inflammatory mediators as an adaptive response. The objective of the present study was to determine the consequences of HO-1 modulation in the murine collagen-induced arthritis (CIA) model. METHODS: DBA/1J mice were treated with an inhibitor of HO-1, tin protoporphyrin IX (SnPP), or with an inducer of HO-1, cobalt protoporphyrin IX (CoPP), from day 22 to day 29 after CIA induction. The clinical evolution of disease was monitored visually. At the end of the experiment, joints were examined for histopathologic changes. Cytokine levels in paws were measured by enzyme-linked…

Metalloporphyrinsmedicine.medical_treatmentImmunologyArthritisProtoporphyrinsInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]MiceRheumatologyFibrosismedicinePerception and Action [DCN 1]Immunology and AllergyAnimalsPharmacology (medical)Enzyme InhibitorsChronic inflammation and autoimmunity [UMCN 4.2]biologybusiness.industryMembrane Proteinsmedicine.diseaseCOPPArthritis ExperimentalHeme oxygenaseEnzyme ActivationPathogenesis and modulation of inflammation [N4i 1]Disease Models AnimalCytokineCyclooxygenase 2Mice Inbred DBAProstaglandin-Endoperoxide SynthasesImmunologyChronic DiseaseHeme Oxygenase (Decyclizing)biology.proteinDisease ProgressionTumor necrosis factor alphaJointsCyclooxygenasemedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1
researchProduct

Fas signaling-mediated T

2018

Fas induces apoptosis in activated T cell to maintain immune homeostasis, but the effects of non-apoptotic Fas signaling on T cells remain unclear. Here we show that Fas promotes TH9 cell differentiation by activating NF-κB via Ca2+-dependent PKC-β activation. In addition, PKC-β also phosphorylates p38 to inactivate NFAT1 and reduce NFAT1-NF-κB synergy to promote the Fas-induced TH9 transcription program. Fas ligation exacerbates inflammatory bowel disease by increasing TH9 cell differentiation, and promotes antitumor activity in p38 inhibitor-treated TH9 cells. Furthermore, low-dose p38 inhibitor suppresses tumor growth without inducing systemic adverse effects. In patients with tumor, rel…

Mice Inbred BALB CNFATC Transcription FactorsNF-kappa BMice NudeCell DifferentiationCancer immunotherapySignal transductionInflammatory Bowel DiseasesT-Lymphocytes Regulatoryp38 Mitogen-Activated Protein KinasesArticleMice Inbred C57BLMiceLymphocyte differentiationNeoplasmsProtein Kinase C betaAnimalsCytokinesHumansFemalefas ReceptorCD4-positive T cellsNature communications
researchProduct

Harmful effect of immunotherapy in children with combined snail and mite allergy

2002

Abstract Background: With respect to allergy, the possibility of cross-reactivity between snail and mite is well recognized, and anecdotal reports suggesting that allergen immunotherapy with mite extract can worsen snail-induced allergy exist. Objective: We describe the effect of immunotherapy in 4 children with snail-mite allergy. Methods: Four children (1 boy and 3 girls; 9-13 years of age) had consistent clinical histories (mild immediate respiratory symptoms after ingestion) and positive skin reactions for allergy to snail. They also had mite-induced asthma and were therefore prescribed subcutaneous specific immunotherapy and subsequently followed. Results: Several months (8-25) after s…

MiteMaleAllergen immunotherapyAllergyAdolescentSnails; Animals; Food Hypersensitivity; Immunotherapy; Humans; Mites; Child; Adolescent; Male; Female; Cross ReactionsSnailsImmunologyCross Reactionsmedicine.disease_causeAllergenFood allergyparasitic diseasesmedicineAnimalsHumansImmunology and AllergyIngestionFood allergy; House dust mite; Immunotherapy; SnailChildAsthmaHouse dust miteMitesintegumentary systembiologyAnimalbusiness.industrymedicine.diseasebiology.organism_classificationSnailImmunologyFemaleImmunotherapybusinessFood HypersensitivityAnaphylaxisHuman
researchProduct

EVALUATION AND POTENTIAL ROLE OF BONE MARROW TISSUE-RESIDENT MEMORY T-CELLS IN PATIENTS WITH PLASMA CELL DYSCRASIAS

2020

Multiple Myeloma Memory T-cells Tissue resident Memory T-cells immunotherapy
researchProduct

Anti-p53-directed immunotherapy of malignant disease

2004

Mutation and aberrant expression of the p53 tumour suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the p53 protein and presented by major histocompatibility complex molecules for T-cell recognition could serve as universal tumour-associated antigens for cancer immunotherapy. Because p53 normally functions as a ubiquitously expressed self-protein, controlling cell-cycle progression and apoptosis, it also represents a paradigm target molecule for tumour-reactive yet self-antigen-specific T cells. Tailoring p53-based cancer immunotherapy thus requires both interference with p53-specific self-tolerance and induction of the entire reperto…

MutationT-Lymphocytesmedicine.medical_treatmentT-cell receptorGenetic TherapyImmunotherapyBiologymedicine.disease_causeMajor histocompatibility complexCell therapyGenes T-Cell ReceptorCancer immunotherapyAntigenNeoplasmsmedicineCancer researchbiology.proteinHumansMolecular MedicineImmunotherapyTumor Suppressor Protein p53ReceptorMolecular BiologyExpert Reviews in Molecular Medicine
researchProduct

Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-al…

1993

A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24 h after epirubic…

Nephrologymedicine.medical_specialtyUrologyUrinary systemUrologyAlpha interferonIntravesical immunotherapyUrineInterferon alpha-2PharmacologyDrug Administration ScheduleIntravesical chemotherapyInterferon-alpha-2bSettore MED/24 - UrologiaInternal medicinemedicineHumansCombined Modality TherapyEpirubicinbusiness.industryInterleukinsInterferon-alphaInterleukinCombined Modality TherapyRecombinant ProteinsClinical trialInterleukins (urinary concentration of)Administration IntravesicalUrinary Bladder NeoplasmsInterleukin-2Interleukin-4Neoplasm Recurrence LocalbusinessInterleukin-1Epirubicinmedicine.drugUrological Research
researchProduct

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

2018

Background: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Methods: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events. Results: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type mutations. KRAS status did not influence nivolumab efficacy in terms of …

OncologyAdultMalemedicine.medical_specialtyCancer Researchmedicine.disease_causePredictive markersArticleProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinoma80 and overHumansProgression-free survivalLung cancerNon-Small-Cell LungneoplasmsAgedAged 80 and overbusiness.industryCarcinomaCancerCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseasedigestive system diseasesProgression-Free Survivalrespiratory tract diseasesNivolumabOncologyAdult; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Mutation; Nivolumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); ImmunotherapyOncology; Cancer Research030220 oncology & carcinogenesisExpanded accessMutationFemaleKRASImmunotherapyNivolumabbusinessNon-small-cell lung cancer
researchProduct